164 institutions hold shares in Immunovant Inc. (IMVT), with 59.23M shares held by insiders accounting for 60.45% while institutional investors hold 103.00% of the company’s shares. The shares outstanding are 97.92M, and float is at 38.77M with Short Float at 8.73%. Institutions hold 40.74% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is RTW Investments LP with over 7.59 million shares valued at $350.69 million. The investor’s holdings represent 7.75% of the IMVT Shares outstanding. As of Dec 30, 2020, the second largest holder is Blackrock Inc. with 4.8 million shares valued at $221.69 million to account for 4.90% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 3.88 million shares representing 3.96% and valued at over $179.15 million, while State Street Corporation holds 1.91% of the shares totaling 1.87 million with a market value of $86.33 million.
Immunovant Inc. (NASDAQ: IMVT) is -67.85% lower on its value in year-to-date trading and has touched a low of $8.34 and a high of $53.75 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The IMVT stock was last observed hovering at around $15.78 in the last trading session, with the day’s loss setting it -0.93%.
Currently trading at $14.85, the stock is -34.88% and -59.59% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.07 million and changing -5.89% at the moment leaves the stock -57.31% off its SMA200. IMVT registered -5.59% loss for a year compared to 6-month gain of -55.50%. The firm has a 50-day simple moving average (SMA 50) of $30.67 and a 200-day simple moving average (SMA200) of $39.67.
The stock witnessed a -62.14% loss in the last 1 month and extending the period to 3 months gives it a -69.63%, and is -12.70% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.29% over the week and 11.56% over the month.
Distance from 52-week low is 78.06% and -72.37% from its 52-week high.
Immunovant Inc. (IMVT) Analyst Forecasts
Immunovant Inc. quarterly earnings per share for the current quarter are estimated at -$0.33.The EPS is expected to grow by 16.20% this year.
Immunovant Inc. (IMVT) Insider Activity
The most recent transaction is an insider purchase by Butchko Julia G., the company’s Chief Dev. & Tech. Officer. SEC filings show that Butchko Julia G. bought 5,000 shares of the company’s common stock on Sep 11 at a price of $38.17 per share for a total of $0.19 million. Following the purchase, the insider now owns 5000.0 shares.
Immunovant Inc. disclosed in a document filed with the SEC on Sep 04 that Roivant Sciences Ltd. (10% Owner) bought a total of 380,000 shares of the company’s common stock. The trade occurred on Sep 04 and was made at $33.00 per share for $12.54 million. Following the transaction, the insider now directly holds 47.59 million shares of the IMVT stock.